The Strategy for the Development of the Pharmaceutical Industry of the Russian Federation for the Period up to 2030: Growth or Stagnation?

The article analyzes the Strategy for the Development of the Pharmaceutical Industry of the Russian Federation until 2030 in the context of continuity with the previous strategy (until 2020) and new sanctions realities after 2022. The seriousness of such a challenge to the provision of medicines to Russian citizens as a possible failure to supply the latest innovative drugs to our country is substantiated. The reason for the possible failure is the termination of clinical trials of new drugs in Russia by the world’s largest pharmaceutical manufacturers. The author argues that even the basic version of the Strategy, judging by its target indicators, is not sufficiently focused on the dynamic development of the domestic pharmaceutical industry. Rather, we can talk about stagnation of the industry, and not about its development. Nevertheless, as shown in the article, the pharmaceutical industry of Russia has a chance to avoid stagnation thanks to investments.